Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18501698 | 0.83 | ATM (0.36) | ATMPOLB | |
| SCHEMBL25144018 | 0.83 | ATM (0.36) | ATMPOLB | |
| SCHEMBL25144026 | 0.83 | ATM (0.36) | ATMPOLB | |
| SCHEMBL22179212 | 0.81 | ATM (0.45) | ATMPOLB | |
| SCHEMBL22179217 | 0.81 | ATM (0.45) | ATMPOLB | |
| SCHEMBL18501697 | 0.80 | ATM (0.34) | ATM | |
| SCHEMBL2201585 | 0.78 | POLB (0.48) | ATMPOLB | |
| SCHEMBL18199643 | 0.78 | POLB (0.31) | POLB | |
| SCHEMBL13803799 | 0.78 | ATM (0.47) | ATMPOLB | |
| SCHEMBL18501702 | 0.77 | LMNA (0.35) | ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20210198278-A1 | SECO MACROLIDE COMPOUNDS | SELVITA D.O.O. (HR) | 2021-07-01 | — | — | US | disclosed |
| US-9809602-B2 | Compounds for treating viral infections | INSTITUT PASTEUR KOREA (KR) | 2017-11-07 | — | — | US | disclosed |
| US-20170044181-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | INSTITUT PASTEUR KOREA (KR) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198278-A1 | SECO MACROLIDE COMPOUNDS | SEC61B, SEC16A, SEC61A1 | ATM 4444/4885POLB 3734/4885 |
| US-20170044181-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | HAVCR2, MAVS, EIF2AK2 | ATM 4209/4885POLB 1107/4885 |
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | ATM 4190/4885POLB 4058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.